From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology Chairman of the Department of Cardiology Heartcenter of the University Medical Center Nijmegen, The Netherlands